DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

BIIB·Biogen Inc.

$.
+. (+.%)
After Hours
High
$200.60
Open
$197.63
Market Cap
29.25B
52W High
$219.72
Low
$194.36
P. Close
$199.26
P/E
21.32
52W Low
$121.05
Fwd P/E
11.99
DailyIQ Est.
$232.25
Technical Score (1D)
50
NEUTRAL
News Sentiment
47
MIXED
Biogen’s Q2 2026 earnings are projected to decline double‑digits as analysts flag ongoing pipeline challenges, a forecast that may prompt a downward revision to guidance. BofA Securities has lifted its price target to $217, reflecting a more optimistic view of the pipeline and earnings prospects, which could buoy sentiment ahead of the earnings release. In contrast, Morgan Stanley trimmed its target to $222 while keeping an equal‑weight rating, indicating a modest valuation adjustment that may temper short‑term enthusiasm. RBC Capital and Jefferies have also raised their targets to $242 and $255 respectively, underscoring a broader bullish consensus on Biogen’s product pipeline. HSBC’s modest upgrade to $157 highlights confidence in upcoming product approvals, adding to the mixed analyst outlook. The company’s forecast of $164 million in Q2 and $290–$320 million in Q3 milestone and R&D charges will further erode earnings, reinforcing the need for cautious interpretation of the earnings guidance. These developments suggest that the next 1–10 trading days will be dominated by the earnings announcement, with market participants weighing the impact of the projected earnings hit against the optimistic price‑target revisions. Traders should watch the Q2 earnings release for any updates on revenue from flagship drugs and any adjustments to the full‑year outlook. Additionally, keep an eye on regulatory milestones for key therapies and any new data presented at upcoming conferences that could shift the pipeline narrative.
Earnings Summary
Biogen Inc. is a global biotechnology company focused on discovering and delivering therapies for neurological and neurodegenerative diseases, operating primarily in the drug manufacturing sector with a portfolio that includes established brands such as TECFIDERA and TYSABRI. In the most recent reporting cycle, Biogen posted Q1 2026 revenue of $2.48 billion, up from $2.28 billion in Q4 2025, while Q2 2026 revenue remains unreported; EPS for Q1 2026 was $3.57 versus an estimate of $2.95, marking a sixth consecutive earnings‑beat in the last 12 quarters, and Q2 2026 EPS is pending. Historically, the company has maintained a streak of EPS beats across six quarters, though revenue has fluctuated—down from $2.45 billion in Q4 2024 to $2.28 billion in Q4 2025 before rebounding in Q1 2026—illustrating resilience amid pipeline challenges. The Q1 2026 EPS beat of 21% over estimates underscores Biogen’s ability to manage cost pressures, while the projected decline in Q2 2026 earnings highlights the impact of upcoming milestone and R&D charges. Analysts also note that the company’s guidance for 2026 remains conservative, reflecting uncertainty around new product approvals. Recent analyst commentary notes that Biogen’s Q2 2026 earnings are expected to decline double‑digits, prompting mixed price‑target revisions: BofA lifted its target to $217, while Morgan Stanley trimmed to $222, and RBC and Jefferies raised to $242 and $255, respectively, reflecting divergent views on the pipeline’s trajectory. Investors should watch the Q2 2026 earnings release for guidance updates, potential adjustments to the full‑year outlook, and any regulatory milestones for flagship products, as these factors will likely shape short‑term sentiment and valuation. Key will be the company’s ability to sustain revenue growth from established therapies while navigating R&D charges and pipeline developments, and watch for updates on the ALS therapy status and guidance revisions that could influence the 2026 outlook.

EPS

EstBeatMiss
$1.05$2.30$3.55$4.80$6.05Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.06 - -
Q1'26$2.95$3.57+20.9%
Q4'25$1.63$1.99+22.4%
Q3'25$3.88$4.81+23.9%
Q2'25$3.88$5.47+41.0%
Q1'25$2.95$3.02+2.4%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.6B$2.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.5B - -
Q1'26$2.2B$2.5B+10.2%
Q4'25$2.2B$2.3B+1.4%
Q3'25 - $2.5B -
Q2'25 - $2.6B -
Q1'25 - $2.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BIIB Stock Snapshot

BIIB is currently trading at $199.15, giving Biogen Inc. a market cap of 29.25B and a P/E ratio of 21.3. Today's range spans $194.36–$200.60, with shares opening at $197.63 and moving down $0.11 (0.1%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 47/100.

Over the past year BIIB has traded between $121.05 and $219.72 - the current price is +64.5% off the 52-week low and -9.4% from the high. 45 analysts cover the stock with a Buy consensus and a mean 12-month target of $222.83 (range $157.00–$300.00), implying upside of +11.9%.

BIIB trades at $199.15 (in the upper portion of its 52-week range within $121.05–$219.72) - and the HOLD signal (50/100) reflects a market that's fairly priced relative to near-term expectations rather than one that's mispriced in either direction. (P/E: 21.3) At 29.25B in Healthcare market cap, neutral sentiment (47/100) confirms the lack of near-term narrative catalyst. The thesis is intact; the timing is patient.

The 52-week range of $121.05–$219.72 for BIIB provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $199.15 (in the upper portion of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 50/100 and neutral news backdrop (47/100) don't break the tie yet, but they narrow the probability distribution toward the upside.